AR FY2025:
- Unit III (Hyderabad): New DCS-automated blocks adding 215 KL reactor volume, doubling core CMS molecule capacity from 15 MT to 30 MT, plus a 4 KL mini-plant — commercial operations
slated for H2 FY 2025-26. - Unit I (Peptides): Multi-modular peptide facility increases peptide synthesis capacity from 0.5
KL to 6.37 KL - Unit II (GDS): Specialty API enhancements include doubling Rotigotine and Dorzolamide lines
and expanding Ezetimibe capacity from 8 MTPA to 12 MTPA.
Disc: Not invested, tracking closely